Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?

Hellenic Journal of Nuclear Medicine

Volumn 15, Issue 3, 2012, Pages

  Bantis, Athanasios ^a   Grammaticos, Philip ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b not available   (Greece)

Author keywords

Bone scan; Gleason's score; Prostate cancer; Prostate specific antigen; PSA specificity

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; MEDRONATE TECHNETIUM TC 99M; MITOXANTRONE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; BONE SCINTISCANNING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; FOLLOW UP; GLEASON SCORE; HUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION;

EID: 84871889373     PISSN: 17905427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18: 581-92 (Pubitemid 46359643)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
3. Parkin DM, Bray F, Ferlay J et al. Cancer Incidence, Mortality and Prevalence Worldwide, GLOBOCAN 2002, American Cancer Society. Cancer J Clin 2005; 55: 74-108.
4. Bantis A, Vasiliou O. Prostate cancer incidence, mortality, total and free prostate specific antigen. Hell J Nucl Med 2009; 12(2): 106-9.
5. Dimopoulos K. Urology in: Neoplasia of the prostate. 5th edn. Paschalidis Publishing Co., Athens 1998; 379-402.
6. Simopoulos AP. The traditional diet of Greece and cancer. Eur J Cancer Prev 2004; 13: 219-30. (Pubitemid 38780680)
7. Bouchardy C, Fioretta G, Rapiti E et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008; 123: 421-9. (Pubitemid 351842029)
8. Mettlin CJ. Cancer epidemiology 50 years later. Cancer 1998; 183: 1275-7.
9. Schroeder FH, Hugosson J, Roobol MJ et al. Prostate cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366(11): 981-90.
10. Stamatiou K, Alevizos A, Mariolis A et al. Do clinically insignificant tumours of the prostate exist? Urol int 2008; 81: 379-82.
11. Moutzouris G, Barbatis C, Plasitiaris D et al. Incidence and histological findings of unsuspected prostatic adenocarcinoma in radical cystoprostatectomy for transitional cell cancer of the bladder. Scand J Urol Nephrol 1999; 33: 27-30. (Pubitemid 29359280)
12. *-R Psa 1995: p. 1-4.
13. Dimasis N. The role of PSA in diagnosis and follow-up of prostate cancer. Archives of the 2nd Seminar of Clinical Oncology. Papyros Press, Thessaloniki 19-21/9/2002, 153-69 (in Greek).
14. Tchetgen MBN, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin N America 1997; 24(2): 283-91. (Pubitemid 27169252)
15. Morrell CH, Brant LJ, Sheng S, Metter EJ. Screening for prostate cancer using multivariate mixed-effects models. J Appl Stat 2012; 39(6): 1151-75.
16. Andriole GL, Catalona WJ. Using PSA to screen for prostate cancer. The Washington University experience. Urol Clin N Amer 1993; 20: 647-52.
17. Catalona WJ, Richie JP, Ahmann FK et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-7.
18. Cooperative Group for Diagnosis of Prostate Cancer. A multicenter study on the detection of prostate cancer by digital rectal examination and prostate-specific antigen in men with or without urinary symptoms. Cooperative Group for Diagnosis of Prostate Cancer. Eur Urol 1997; 32(2): 133-9.
19. Carter B. Prostate cancers in men with low PSA levels-Must we find them? N Eng J Med 2003; 349: 335-42.
20. Conte C. Prostate cancer: to screen or not. NRTA Bulletin 2001; 42: 7-8.
21. Andriole GL, Grubb III RL, Buys SS et al. Mortality results from a randomized prostate cancer screening trial. NEJM 2009; 360(13): 1310-9.
22. Schroeder Fh, Hugosson G, Roobol MJ et al. Screening and prostate cancer mortality in a randomized European study. NEJM 2009; 360(13): 1320-8.
23. Heijnsdijk EA, Wever EM, Auvinen A et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367(7): 595-605.
24. Schrφder FH, Hugosson J, Carlsson S et al. Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012; 62(5): 745-52.
25. Andriole GL, Levin DL, Crawford ED et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 433-8. (Pubitemid 40528606)
26. Schrφder FH. Screening for prostate cancer. Eur J Cancer 2011; 47 Suppl 3: S164-70.
27. Vickers AJ, Roobol MJ, Lilja H. Screening for prostate cancer: early detection or overdetection? Ann Rev Med 2012; 63: 161-70. Epub 2011 Nov 3.
28. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350(22): 2239-4.
29. Crawford D. PSA testing: What is the use? The Lancet 2005; 365: 1447-8.
30. Damber JE, Aus G. Prostate cancer. The Lancet 2008; 371: 1710-21. (Pubitemid 351671887)
31. Parker C. What (if anything) to do about low-risk prostate cancer. The Lancet 2012; 379: 1078-9.
32. Prostate cancer: send away the PSA? The Lancet 2012; 380: 307.
33. Wilt TJ, Brawer MK, Jones KM et al. Radical prostectomy versus observation for localized prostate cancer. NEJM 2012; 367(3): 203-13.
34. Freedland SJ, Sutter ME, Dorey F et al. Defining the ideal cut-point for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61(2): 365-9. (Pubitemid 36206534)
35. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer. NEJM 2004; 351(15): 1502-12. (Pubitemid 39315317)
36. Chism DB, Hanlon AL, Horwitz EM et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 380-5. (Pubitemid 38622589)
37. Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. NEJM 2009; 361(8): 745-55.
38. Klatte T, Klatte D, Bφhm M, Allhoff EP. Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis. Urologe A 2006; 45: 1293-4 & 1296-9.
39. Thompson Jr IM, Tangen CM. Prostate cancer-Uncertainty and a way forward. NEJM 2012; 367(3) 270-1.
40. Cheng L, Montironi R, Bostwick DG et al. Staging of prostate cancer. Histopathology 2012; 60(1): 87-117.
41. Benson MC, Whang IS, Pantuck A et al. Prostate specific antigen density: a means of distinguishing benign prostatic hyperthrophy and prostate cancer. J Urol part 2 1992; 147: 817-20.
42. Oh JJ, Hong SK, Lee JK et al. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int 2012 Apr 30. doi: 10.1111/j.1464-410X.2012.11182.x.
43. Heijnsdijk EAM, Wever EM, Auvinen A et al. Quality of life effects of prostate specific antigen screening. N Engl J Med 2012; 367(7): 595-605.
44. Vickers AJ, Brewster SF. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol 2012; 5(4): 162-8.
45. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351(2): 125-35.
46. Riffenburgh RH, Amling CL Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer. Prostate Cancer Prostatic Dis 2003; 6(1): 39-44. (Pubitemid 36432618)
47. Anderson JR, Strickland D, Corbin D et al. Age-specific reference ranges for serum prostate-specific antigen. Urology 1995; 46(1): 54-7.
48. Roddam AW, Duffy MJ, Hamdy FC et al NHS Prostate Cancer Risk Management Programme. Use of prostate-specific antigen (PSA) ¡for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005; 48(3): 386-99; discussion 398-9
49. Chakraborty L, Ahmed AN, Paul BK et al. Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer. Mymensingh Med J 2012; 21(1): 98-102.
50. Assadi M, Nabipour I, Eftekhari M et al. Diagnostic role of whole body bone scintigraphy in atypical skeletal tuberculosis resembling multiple metastases: a case report. J Med Case Rep 2009; 3: 141.
51. Wang C, Shen Y. Study on the distribution features of bone metastases in prostate cancer. Nucl Med Commun 2012; 33(4): 379-83.
52. Matsumura Y, Otani T, Yoneda T et al. [The criteria for avoiding unnecessary computerized tomography and bone scan in staging patients with newly diagnosed prostate cancer: retrospective study of patients at Matsusaka Chuo General Hospital]. Nippon Hinyokika Gakkai Zasshi 2007; 98: 764-9.
53. Little B, Young M. How to use PSA to screen for prostate cancer. Int J Clin Pract 2003; 57(1): 40-2. (Pubitemid 36181747)
54. Aus G, Abbou CC, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546-51. (Pubitemid 41278578)
55. The Japanese Urological Association. Prostate Cancer: Clinical Practice Guideline. Tokyo: Kanehara Shuppan Kabushikikaisha; 2006; p. 59-60.
56. Lucignani G. Advances in prostate cancer imaging techniques and strategies. Eur J Nucl Med Imag 2008; 35: 1019-25.
57. Pal RP, Thiruudaian T, Khan MA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl 2008; 10: 890-5.
58. Bantis A, Zissimopoulos A, Kalaitzis C et al. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment. Hell J Nucl Med 2008; 11(1): 21-5. (Pubitemid 351649753)
59. Ryan CJ, Elkin EP, Small EJ et al. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 2006; 24: 396-402. (Pubitemid 44311554)
60. Wolff JM, Zimny M, Borchers H et al. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998; 33: 376-81. (Pubitemid 28230261)